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Genetic alterations occurring on human chromosome arm 1p are common in many types of cancer including lung, breast,
neuroblastoma, pheochromocytoma, and colorectal. The identification of tumour suppressors and oncogenes on this arm has been
limited by the low resolution of current technologies for fine mapping. In order to identify genetic alterations on 1p in small-cell lung
carcinoma, we developed a new resource for fine mapping segmental DNA copy number alterations. We have constructed an array
of 642 ordered and fingerprint-verified bacterial artificial chromosome clones spanning the 120 megabase (Mb) 1p arm from 1p11.2
to p36.33. The 1p arm of 15 small-cell lung cancer cell lines was analysed at sub-Mb resolution using this arm-specific array. Among
the genetic alterations identified, two regions of recurrent amplification emerged. They were detected in at least 45% of the samples:
a 580kb region at 1p34.2–p34.3 and a 270kb region at 1p11.2. We further defined the potential importance of these genomic
amplifications by analysing the RNA expression of the genes in these regions with Affymetrix oligonucleotide arrays and
semiquantitative reverse transcriptase–polymerase chain reaction. Our data revealed overexpression of the genes HEYL, HPCAL4,
BMP8, IPT, and RLF, coinciding with genomic amplification.
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Greater than 42000 new cases of small-cell lung cancer (SCLC) are
diagnosed annually in the United States, representing approxi-
mately 20% of all new lung cancer cases. Median survival time is
12–36 months and the majority of patients eventually die from the
disease (Minna et al, 2003). Advancing our understanding of the
molecular characteristics of SCLC may lead to the ability to better
diagnose and treat the disease. One approach to this is the
detection of regions of genetic alteration in the tumour genome in
order to identify the genes that are causal to the disease.
Identification of novel genetic changes correlated to specific
human malignancies has typically been a tedious and laborious
process. Recently, high-throughput and high-resolution detection
of such alterations has been made possible through the use of
bacterial artificial chromosome (BAC) array comparative genomic
hybridisation (CGH) (Pinkel et al, 1998). This technique has been
applied to map alterations across the genome at 1 megabase (Mb)
resolution (Snijders et al, 2001; Greshock et al, 2004), at higher
resolution for specific chromosomal regions and chromosome
arms in several tumour types (Buckley et al, 2002; Garnis et al,
2003, 2004a), and, most recently, the whole human genome
(Ishkanian et al, 2004).
Approximately 120Mb of DNA span human chromosome arm
1p. Multiple regions on this chromosome arm have been
implicated in SCLC and non-small-cell lung cancer (NSCLC)
(Girard et al, 2000; Nomoto et al, 2000; Chizhikov et al, 2001;
Ashman et al, 2002). Here, we describe the construction of a
unique resource for analysing 1p. In all, 642 fingerprint-verified,
physically mapped, overlapping BAC clones serve as target DNA
for high-resolution BAC array CGH. Using this resource, we
identified novel regions of DNA alteration in SCLC cells. We
further defined the role of these alterations by employing
Affymetrix oligonucleotide arrays and semiquantitative reverse
transcriptase–polymerase chain reaction (RT–PCR) to analyse
gene expression.
MATERIALS AND METHODS
BAC array construction and CGH
To design a minimal tiling path, BAC clones from the RPCI-11
library (Osoegawa et al, 2001) were selected from the FPC
(Fingerprinted Contigs) database (International Human Genome
Mapping Consortium, 2001). Wherever possible, sequenced and
overlapping clones were chosen. Clones were obtained from
glycerol stocks of the RPCI-11 library. DNA isolation and
restriction enzyme digestion was performed as described pre-
viously (Marra et al, 1997). Each clone’s identity was verified by
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scomparing its HindIII DNA fingerprint to that found in the FPC
database. The BAC DNA amplification, array printing, hydridisa-
tion, and analysis were performed as described previously (Garnis
et al, 2004a). A log2 signal ratio of zero represents the most
common copy number between the sample and normal reference
DNA. The array was subjected to normal/normal hybridisation in
order to eliminate clones that deviated from 0 by greater than
þ0.2 or less than  0.2. Clones with standard deviations among
the triplicate spots greater than 0.075 were excluded from further
analysis. A gain of copy number was defined as a log2 ratio of
greater than 0.2, and a loss as a log2 ratio of less than  0.2. The
average log2 ratio of two or more adjacent clones was required to
be above the threshold in order for a region of alteration to be
defined.
Cell lines
The lung cancer cell lines used were established at the National
Cancer Institute (Phelps et al, 1996), with the exception of HCC33,
which was generated at the Hamon Center for Therapeutic
Oncology Research (Gazdar et al, 1998). NHBEC (normal human
bronchial epithelial cells) and SAEC (small airway epithelial cells)
were obtained from Clonetics (San Diego, CA, USA). HBEC2-KT,
HBEC3-KT, HBEC4-KT, and HBEC5-KT are normal human
bronchial epithelial cell lines immortalised with CDK4 and htert
(Ramirez et al, 2004). Culturing conditions and DNA isolation
were described previously (Girard et al, 2000). RNA isolation was
carried out using the RNeasy Midi kit (Qiagen, Valencia, CA,
USA), together with in-column DNase1 treatment.
Gene expression profiling using Affymetrix arrays
RNA fluorescent-labelling reaction and hybridisation were per-
formed using the Affymetrix GeneChips HG-U133A and HG-
U133B according to the manufacturer’s instructions (http://
www.affymetrix. com). The arrays consist of 22283 (HG-U133A)
and 22645 (HG-U133B) probe sets, which together amount to
24698 unique genes based on Unigene build 163. Total RNA (5mg)
was used for each reaction. Microarray analysis was performed
using Affymetrix MicroArray Suite 5.0 and an in-house Visual
Basic software MATRIX 1.24 (Girard et al, manuscript in
preparation). Briefly, array data were median normalised and
samples (or averages of samples) were compared against each
other by calculating log ratios for each gene. Specifically, a lower
signal threshold was set at 100 to reduce the amount of noise and
the log ratio of one signal vs another was calculated by dividing the
signals and computing the log base 2. These log ratios were
calculated only when both signals were Present (i.e. the signal-
associated detection P-values were less than 0.05) or when the
higher signal was Present and the lower signal was Absent (P-value
more than 0.05).
Gene expression profiling using semiquantitative RT–PCR
Analysis was conducted as described previously (Garnis et al,
2004b). PCR conditions were: one cycle of 951C, 1min; amount of
cycles as listed for each gene of 951C, 30s; 621C, 30s; 721C, 1min
and a 10min extension at 721C, except Notch2 where annealing
temperature was 551C. Gene-specic primers were used to assay the
quantity of: HEYL (50agaatccctagtggggctgt30;5 0gatgcaagtccttgaccaca30;
35 cycles), HPCAL4 (50tgctgatggaaggaacaaca30;5 0tgtgctttgtggcaagt
ctc30; 35 cycles), BMP8 (50ttatctgcgcctccattttc30;5 0tatgtgccaactctgctt
cg30; 35 cycles), PPIE (50gaagccaaagcagaaggtga30;5 0atatcccaaatgctg
cttgc30; 32 cycles), IPT (50ggagggaggggtatgtttgt30;5 0gacacatcagcca
cacaagg30; 30 cycles), RLF (50tttgatgattgggagccttc30;5 0aaaggtgggattg
cagtcag30; 35 cycles), CAP1 (50catccagggcagttaatgga30;5 0agcatgaca
gggaaaaggag30; 30 cycles), Notch2 (50ggaatggtggcagaactgat30;
50ggcatggtactcttggcact30; 30 cycles). b-actin expression levels were
used to normalise samples.
Statistical analysis of Affymetrix expression data
Only those Affymetrix probe sets that demonstrated a detection
score of Present or Marginal (Po0.06) in at least 50% of the
samples were analysed further. Statistically significant expression
changes were identified using a Mann–Whitney U-test for those
genes that passed the detection criteria. For determination of
expression differences between the SCLC and normal cell lines, a
two-tailed test was utilised and the direction of change noted. In
determining a correlation between overexpression and genomic
amplification, a one-tailed test was used. Genes were considered to
exhibit aberrant expression if the P-value crossed a threshold of
0.05.
Statistical analysis of RT–PCR expression data
A ratio was obtained for each sample by dividing the intensity of
the gel band for the gene of interest by the corresponding b-actin
band. These ratios were then compared, using the Mann–Whitney
U-test as described above, between samples exhibiting genomic
amplification and samples exhibiting retention in the two regions
of interest. If the P-value for the comparison was less than 0.05,
and the data were consistent with the Affymetrix analysis, the gene
was considered to have different expression between the two
groups.
RESULTS AND DISCUSSION
The minimal tiling path for the 1p array consists of 642 BAC
clones, of which 373 (58%) are sequenced clones, covering from
1p11.2 to 1p36.33. FPC clone order was compared to the golden
path assembly on the July 2003 version of the UCSC Human
Genome Browser (http://genome.ucsc.edu) (Kent et al, 2002) using
the sequence accession number, BAC end sequence, or existing
FISH maps. In total, 438 (68%) clones are confirmed with at least
one of these methods and the remaining 204 BACs are ordered by
their FPC location. The complete clone list has been made publicly
available at http://www.bccrc.ca/cg/ArrayCGH_Group.html.
We chose to include only cell lines for the initial investigation
with this array. Tumour samples from SCLC are infrequently
available for research purposes and the DNA obtained from
tumour samples is usually of lower yield and lower quality than
that obtained from cell lines. In all, 15 cell lines generated from
SCLC, described in Table 1 (Phelps et al, 1996), were hybridised to
the 1p array. Copy number alterations were detected in each of the
15 cell lines, ranging in size from 0.2 to 28Mb. The locations and
sizes of the alterations are summarised in Figure 1. Two cell lines
(NCI-H1672, NCI-H2171) showed deletions only, eight (NCI-H82,
NCI-H187, NCI-H289, NCI-H378, NCI-H889, NCI-H1184, NCI-
H2195, NCI-H2227) showed amplifications only, and five (NCI-
H526, NCI-H1607, NCI-H1963, NCI-H2141, HCC33) showed both
amplifications and deletions. Three examples of array CGH
profiles are shown in Figure 2, illustrating the detection of sub-
Mb size copy number changes, as well as multiple distinct
alterations along the 1p arm in NCI-H1672, NCI-H2141, and
HCC33.
Figure 3A shows the complex profile of cell line NCI-H526. We
observe two distinct deletions at 1p36.12–p36.13 and at 1p36.21–
p36.22. The area of retention between these deletions is
approximately 2.5Mb in size. The use of lower resolution
techniques may have defined this region as one large deletion.
Additionally, array CGH analysis was able to detect two sub-Mb
alterations: a 0.5Mb amplification at 1p35.2 and a 0.44Mb
amplification at 1p11.2–p12. Alterations of these sizes would
Array CGH and gene expression analysis of 1p in SCLC
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slikely have been overlooked when using a CGH array with greater
than 1Mb resolution. In order to determine if the changes in array
signal intensities reflect true copy number alterations, we selected
three loci for FISH experiments. The loci and their associated
clones’ locations are noted in Figure 3A. As seen in metaphase
nuclei of NCI-H526, 548I13 shows three copies, whereas 476E5
shows two copies (Figure 3B). In a second experiment, 548I13
again shows three copies, whereas 385C11 shows six copies
(Figure 3C). The normalised ratio of BAC 548I13 is at zero, even
though it has three copies, as NCI-H526 has greater than a diploid
Table 1 SCLC cell lines analysed by array CGH and Affymetrix array (Phelps et al, 1996)
Name Morphology Sex Age (years) Source of specimen Stage at diagnosis
NCI-H82 Variant M 41 Pleural effusion Extensive
NCI-H187 Classical M 47 Pleural effusion Extensive
NCI-H289 Variant F 45 Pleural effusion Extensive
NCI-H378 Classical F 66 Lung Extensive
NCI-H526 Variant M 55 Bone marrow Extensive
NCI-H889 Classical F 69 Lymph node Extensive
NCI-H1184 Classical M 42 Lymph node Limited
NCI-H1607 Classical M 54 Lymph node Extensive
NCI-H1672 Classical M 58 Lung Limited
NCI-H1963 Classical M 56 Lung Limited
NCI-H2141 Classical M 58 Lymph node Extensive
NCI-H2171 Classical M 50 Pleural effusion Extensive
NCI-H2195 Classical M 67 Bone marrow Extensive
NCI-H2227 Classical M 54 Lung Extensive
HCC33 Classical M 52 NA NA
SCLC¼small-cell lung cancer; CGH¼comparative genomic hybridisation; M¼male; F¼female; NA¼not applicable.
Losses Gains
H
C
C
3
3
N
C
I
-
H
2
1
7
1
N
C
I
-
H
2
1
4
1
N
C
I
-
H
1
9
6
3
N
C
I
-
H
1
6
7
2
N
C
I
-
H
1
6
0
7
N
C
I
-
H
5
2
6
N
C
I
-
H
8
2
N
C
I
-
H
1
8
7
N
C
I
-
H
2
8
9
N
C
I
-
H
3
7
8
N
C
I
-
H
5
2
6
N
C
I
-
H
8
8
9
N
C
I
-
H
1
1
8
4
N
C
I
-
H
1
6
0
7
N
C
I
-
H
1
9
6
3
N
C
I
-
H
2
1
4
1
N
C
I
-
H
2
1
9
5
N
C
I
-
H
2
2
2
7
H
C
C
3
3
Recurrently
amplified
Region 1
Recurrently
amplified
Region 2
1p36.33
1p36.32
1p36.31
1p36.23
1p36.22
1p36.21
1p36.13
1p36.12
1p36.11
1p35.3
1p35.2
1p35.1
1p34.3
1p34.2
1p34.1
1p33
1p32.3
1p32.2
1p32.1
1p31.3
1p31.2
1p31.1
1p22.3
1p22.2
1p22.1
1p21.3
1p21.2
1p21.1
1p13.3
1p13.2
1p13.1
1p12
1p11.2
1p11.1
Figure 1 Alignment of 1p array CGH profiles from 15 SCLC cell lines. Gains are shown to the right of the chromosome arm and losses to the left. Two
recurrent amplifications are revealed, one at 1p34.2–p34.3 and the second at 1p11.2.
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snumber of chromosomes. These data demonstrate the ability of
array CGH to distinguish loci that differ in copy number by 0.67
times (3 vs 2) and two times (3 vs 6).
Two regions of sub-Mb amplification were common among 45–
50% of the cell lines. Region 1 is a 580kb amplification at 1p34.2–
p34.3, and Region 2 is a 270kb amplification at 1p11.2, as
displayed in Figure 1.
The Region 1 amplification occurs in seven of the 15 cell lines
and contains BACs 314P18, 428O4, 204L3, and 115D7. Notably, in
four of the seven cell lines (NCI-H378, NCI-H889, NCI-H1963,
HCC33), the amplified region shows at least one BAC with a log2
ratio greater than 2.5, corresponding to a greater than five-fold
increase in signal from normal, and indicating high-level
amplification. The region contains 12 genes, listed in Table 2.
Conspicuously, MYCL1, a gene first described in SCLC (Nau et al,
1985) is present in this region. Of the 15 cell lines described here,
all but HCC33 were previously analysed for MYC family
amplifications using Southern blot analysis (Johnson et al, 1996).
NCI-H378 and NCI-H889 were described as having MYCL1
amplification, and in the current study, these amplification were
also detected. We describe NCI-H526, NCI-H1184, NCI-H2141, and
NCI-H1963 as having amplifications in the MYCL1 region;
however, the Southern analysis did not find MYCL1 gene
amplification in these cell lines. A possible explanation is that
these cell lines do contain the amplification but they did not meet
the four-fold signal increase cutoff necessary for the determination
of an amplification in the Southern blot analysis. All other cell lines
in which MYCL1 amplifications were not seen by Johnson et al
were also not seen amplified in the present study.
Previous conventional CGH studies of SCLC have revealed
amplification in the MYCL1 region. In SCLC cell lines, Levin et al
(1994) detected amplification of chromosome bands 1p22–32 in
nine of 18 samples (Levin et al, 1994). (MYCL1 was initially
mapped to 1p32 (Nau et al, 1985), then reassigned to 1p34.3
(Speleman et al, 1996)). Ried et al (1994) studied primary SCLC
tumours and observed amplification of 1p32 in two of 13 cases
(Ried et al, 1994). While these observations do implicate the
MYCL1 locus, the regions identified are approximately 40 and
10Mb in size, respectively, and contain hundreds of genes, making
the identification of the specific genes affected by the amplification
virtually impossible. Using high-resolution array CGH, we have
defined the precise boundaries of the amplification in each cell
line, with NCI-H2141 and HCC33 having amplified regions of less
than 600kb in size. We also determined that the minimal region of
alteration at 1p34.2–p34.3 is 580kb in size and contains 11 genes
in addition to MYCL1. This demonstrates the resolving power of
array CGH to identify very small alterations and to delineate
minimal regions of alteration. Previous studies that focused
only on the presence and not the extent of MYCL1 amplification
may have overlooked the potential involvement of neighbouring
genes.
The Region 2 amplification is a 270kb amplification occurring
in eight cell lines and contains BACs 385C11, 498H23, and 114O18.
The 114O18 is the last BAC mapped to the centromeric end of the
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Figure 2 Array CGH profiles of SCLC cell lines. (A) Profile of NCI-
H1672 demonstrating a large deletion at 1p31.2–p34.1. (B) Profile of NCI-
H2141 demonstrating a small amplification at 1p34.3, deletion at 1p13.1–
p13.3, and amplification at 1p11.2–p12. (C) Profile of HCC33 showing a
small amplification at 1p34.2–p34.3 and multiple distinct deletions from
1p34.1 to p36.33.
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Figure 3 (A) Array CGH profile of SCLC cell line NCI-H526
demonstrating multiple segmental alterations across the 1p arm. Three
BACs used in FISH analysis are indicated. (B) FISH analysis of 548I13 vs
476E6, indicating that the presence of three copies of 548I13 and two
copies of 476E6. (C) FISH analysis of 548I13 vs 385C11, indicating the
presence of three copies of 548I13 and six copies of 385C11. FISH
experiments were conducted as described previously (Henderson et al,
2004).
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s1p arm. Two genes, ADAM30 and Notch2, reside in this region.
ADAM30 is a member of the family of membrane proteins that
contain a disintegrin and metalloprotease domain and its normal
expression has only been detected in the testis (Cerretti et al,
1999). While ADAM30 itself has not been implicated in cancer, a
number of other ADAM genes have, such as ADAM9 in breast
cancer (O’Shea et al, 2003) and ADAM12 in bone cancer (Tian
et al, 2002). Notch2 and the three other genes in its family, Notch1,
Notch3, and Notch4, code for evolutionarily conserved Type 1
transmembrane receptor proteins (Artavanis-Tsakonas et al,
1999). While these proteins have been widely studied, investiga-
tions into their possible roles in cancer have yielded a number of
studies with differing conclusions. Notch1 was first described as
being involved in a balanced translocation with TCRb and a
constitutively active Notch1 was oncogenic in T cells (Ellisen et al,
1991). Notch3 overexpression has been shown in NSCLC (Dang
et al, 2000); however, it has also been demonstrated that
expression of Notch1 and Notch2 induced cell cycle arrest in
SCLC cell lines (Sriuranpong et al, 2001).
We searched for alterations of Regions 1 and 2 in NSCLC. In the
analysis of nine NSCLC cell lines, we detected amplification of
Region 1 in one sample and Region 2 in four samples (data not
shown). In comparison to SCLC, the amplifications in NSCLC
included larger regions and, in the case of Region 1, were at a lower
level. For example, NCI-H520, a lung squamous cell carcinoma, has
a 7Mb amplification containing Region 1, and a 3.2Mb amplifica-
tion containing Region 2. The lower frequency of Region 1
amplification is in agreement with a previous observation that
MYC family gene amplification occurs at a frequency of less than
5% in NSCLC (Bruce Johnson, personal communication), as
opposed to up to 36% in SCLC (Johnson et al, 1996).
The amplification of Region 2 was also detected in NSCLC
tumours, where overexpression of Notch2 was observed (Garnis
et al, 2005).
Table 2 Expression analysis of genes in Region 1 and Region 2 amplifications
Affymetrix U133 probe
set Expression: amplification vs retention
Gene Full name
Affymetrix
ID Accession
Affymetrix
probe
detectable
a
Expression:
SCLC vs
normal Affymetrix RT–PCR
Overall
score
Region 1
HEYL Hairy/enhancer- of-split related with
YRPW motif like
226828_s_at AL040198 Yes P¼0.00332
(up)
P¼0.47754 P¼0.07599 No change
220662_s_at NM_014571 No — —
NT5C1A 50-nucleotidase, cytosolic IA 224529_s_at AY028778 No — — —
HPCAL4 Hippocalcin like 4 222091_at AL136591 Yes P¼0.01098
(up)
P¼0.16783 P¼0.34716 No change
219671_at BE550384 No — —
PPIE Peptidylprolyl isomerase E 229375_at AL526713 Yes P¼0.67684 P¼0.02704
(up)
b
P¼0.23170 No change
202494_at NM_006112 Yes P¼0.06631 P¼0.2317 No change
210502_s_at AF042386 Yes P¼0.84999 P¼0.0603
221615_at AF104013 No — —
BMP8 Bone morphogenetic protein 8 207865_s_at NM_001720 Yes P¼0.00837
(up)
P¼0.01026
(up)
P¼0.04693 (up) Up
235275_at AA610122 Yes P¼0.00111
(up)
P¼0.00295
(up)
207866_at NM_001720 No — —
OXCT2 3-oxoacid CoA transferase 2 220256_s_at NM_022120 No — — —
IPT TRNA isopentenyl transferase
precursor
218617_at NM_017646 Yes P¼0.17806 P¼0.00016
(up)
P¼0.02005(up) Up
MYCL1 Avm oncogene homolog 1, lung
carcinoma derived
Not included on array — — — —
FLJ14490 Hypothetical protein FLJ14490 Not included on array — — — —
CAP1 Adenylyl cyclase-associated protein 1 200625_s_at NM_006367 Yes P¼0.00623
(down)
P¼0.43326 P¼0.38943 No change
213798_s_at AA806142 Yes P¼0.00623
(down)
P¼0.14048 No change
PPT1 Palmitoyl-protein thioesterase 1 200975_at NM_000310 Yes P¼0.15369 P¼0.2317 — No change
RLF Rearranged L-myc fusion sequence 204243_at NM_012421 Yes P¼0.79098 P¼0.00699
(up)
P¼0.03605 (up) Up
Region 2
ADAM30 A disintegrin and metalloproteinase
domain 30
221446_at NM_021794 No — — —
Notch2 Notch homolog 2 202445_s_at NM_024408 No — — P¼0.06030
202443_x_at AA291203 Yes P¼0.00004
(down)
P¼0.16783 No change
212377_s_at AU158495 Yes P¼0.00015
(down)
P¼0.26791 No change
SCLC¼small-cell lung cancer; RT–PCR¼reverse transcriptase–polymerase chain reaction.
aAffymetrix score of Present or Marginal in 450% of samples.
bRT–PCR analysis
failed to confirm the expression difference detected by Affymetrix.
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sGene expression analysis for each of these cell lines was obtained
using Affymetrix GeneChips HG-U133A and HG-U133B. Expres-
sion levels of the genes contained in the Region 1 and Region 2
amplifications were compared between the SCLC cell lines and
normal control cell lines SAEC, NHBEC, and four immortalised
HBEC lines. Additionally, as there is no normal tissue that is
known to be a suitable control for gene expression in SCLC, we
also compared gene expression among cell lines with and without
amplifications in the regions of interest. It has been previously
demonstrated that the overexpression of some of the genes in a
tumour can be attributed to their genomic amplification. Up to
44% of amplified genes (depending on their level of amplification)
were found to be overexpressed in breast cancer cell lines (Hyman
et al, 2002). We further compared the expression levels of these
two sets of SCLC cell lines using semiquantitative RT–PCR
analysis for the genes where a significant difference in expression
was observed in the Affymetrix data. The results for all analyses of
gene expression are detailed in Table 2 and a comparison of
relative expression levels is displayed in Figure 4.
In Region 2, ADAM30 expression was not detected on the
Affymetrix array. Notch2 was underexpressed in SCLC compared
to normal cell lines. This observation is consistent with the
observations of Sriuranpong et al (2001), where overexpression of
Notch2 in SCLC induced cell cycle arrest. No difference in Notch2
expression was observed between SCLC cells with and without the
genomic amplification of Region 2 in either Affymetrix or RTPCR
analyses (see Figure 4B and Table 2). It appears that the
amplification of this region may not have a functional role in
increasing the expression of the genes contained in it.
A number of expression differences in both comparisons were
observed for the genes in Region 1. In comparing SCLC and
normal cells, four genes demonstrated significant differences:
HEYL, HPCAL4, BMP8, and CAP1. CAP1 showed underexpression,
while the other three were overexpressed. The comparison of SCLC
cells with and without amplification of Region 1 revealed three
genes that were overexpressed in the amplified cells: BMP8, IPT,
and RLF. One gene, PPIE, was observed overexpressed in one of its
three Affymetrix probes, but no difference was observed in its
other two probes or the RT–PCR analysis. This may indicate a
problem with that particular probe on the Affymetrix array. All
other genes for which RT–PCR analysis was conducted agreed
with the Affymetrix analysis (see Table 2). BMP8 was the only gene
overexpressed in both comparisons. Owing to the possibility of the
comparison of expression between SCLC and normal cells being
skewed by extremely high expression in the amplified samples, we
compared BMP8 expression between the normal cell lines and the
nonamplified SCLC cells. BMP8 remained overexpressed in SCLC
(data not shown).
HEYL is part of a subfamily of bHLH (basic helix–loop–helix)
transcription factors. These proteins control cell fate decisions
such as segmentation, neurogenesis, and myogenesis (Steidl et al,
2000). The mouse homologue of HEYL has been shown to be a
target of Notch1 signalling during development (Leimeister et al,
2000). As mentioned above, the Notch pathway has been found to
have differing roles in cancer, depending on the tumour type.
HPCAL4 expression has only been detected in the brain. It is
part of neuron-specific calcium-binding protein family; however,
the specific function of HPCAL4 is not known (Kobayashi et al,
1998). HPCAL4 expression was not present in the normal lung cell
lines (based on the detection P-value), but expression was seen in
the SCLC cells. This may be a result of the neuroendocrine nature
of SCLC.
CAP1 is associated with actin and cofilin and allows the rapid
turnover of actin filaments. This is an important function in cell
motility. In yeast, CAP is a component of the Ras pathway;
however, this role has not been identified in humans (Moriyama
and Yahara, 2002). Differential expression of CAP1 has not been
previously detected in cancer; however, a potential role for the
actin and cofilin complexes may be increasing cell motility during
metastasis. A role such as this would imply overexpression of the
genes involved, whereas we have observed underexpression of
CAP1.
BMP8 is a bone morphogenetic protein, part of the TGF-b
superfamily. These proteins play a role in aspects of mammalian
development such as mesoderm determination, neural patterning,
organogenesis, and skeletal patterning (DiLeone et al, 1997). There
have been a number of studies of BMPs in cancer. BMPs were
identified as potential tumour suppressor genes in myeloma
(Hjertner et al, 2001) and prostate cancer (Brubaker et al, 2004).
They were also shown to be overexpressed in oral squamous cell
carcinoma (Jin et al, 2001) and BMP7 was overexpressed in breast
cancer cell lines (Hyman et al, 2002).
RLF has been shown to be in fusion with MYCL1 in SCLC. Kim
et al (1998) detected genomic amplification of RLF in four of 11
MYCL1-amplified SCLC cell lines they studied. Chimeric RLF-
MYCL1 transcripts were detected in NCI-H889, NCI-H1836, and
NCI-H1994 (Kim et al, 1998). RLF contains zinc-finger motifs, and
is related to the Zn-15 transcription factor. It is thought to have a
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Figure 4 Integrating gene expression profiles with genomic alterations. (A) Relative expression of the genes within Region 1. (B) Relative expression of
the genes within Region 2. Each Affymetrix probe set (probe set ID is indicated in brackets), which exhibited a detection P-value of less than 0.06 in 450%
of samples was analysed by dividing the expression value for the gene in each experiment by the average expression value for that gene in the five normal
cell lines. The resultant log2 ratio is displayed colorimetrically according to the legend.
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sgeneral role in transcriptional regulation (Makela et al, 1995). The
RLF-MYCL1 fusion protein has also been detected in SCLC primary
tumours. Its role is thought to be the deregulation of expression of
MYCL1 (Makela et al, 1992). Interestingly, while RLF was originally
identified due to fusion and overexpression with MYCL1, it was not
the cell lines with the highest amplification in which we observed
the highest expression. While NCI-H378 and NCI-H889 show the
highest amplification of the region, and were the only two cell lines
with previously known MYCL1 amplification, NCI-H1184 and
NCI-H1963 both express RLF at higher levels than NCI-H378
and NCI-H889. The observation of increased expression of RLF,
particularly in cell lines that had not been previously studied, lends
additional weight to its implication in SCLC.
The overexpression of IPT was the most significantly associated
with amplification (see Figure 4 and Table 2). IPT catalyses the
transfer of an isopentenyl group from dimethylallyl pyrophosphate
to a tRNA in the biosynthesis of the tRNA cytokinin isopenteny-
ladenosine (Golovko et al, 2000). Isopentenyladenine is an end
product of the mevalonate pathway. Mevalonate is the precursor of
isoprenoid groups that are incorporated into other end products in
addition to isopentyladenine such as sterols and ubiquinone
(Goldstein and Brown, 1990). HMG-CoA reductase catalyses the
conversion of HMG-CoA to mevalonate. Elevated activity of this
protein has been observed in a number of tumour types. The statin
family of drugs are HMG-CoA reductase inhibitors that reduce
levels of mevalonate and its end products. Statins have been
successfully used in the treatment of hypercholesterolaemia, and
have been recently demonstrated to have antiproliferative and
proapoptotic effects in tumours both in vitro and in vivo (Wong
et al, 2002). As the mevalonate pathway has been shown to play an
important role in the maintenance of the malignant phenotype,
IPT, which contributes to the production of an end product, may
have a role in promoting malignancy as well. Its specific function
and contribution remain to be clarified.
We have presented a chromosome arm-specific tiling resolution
BAC array consisting of 642 BAC clones spanning 120Mb of
chromosome arm 1p and profiled 15 SCLC cell lines using this
array. We have reliably detected the previously known MYCL1
amplification, as well as defined a 580kb amplification at 1p34.2–
p34.3, and a novel 270Kb Amplification at 1p11.2. This
demonstrates the ability of high-resolution array CGH to identify
small alterations that may have escaped detection by other means,
and to detect efficiently the chromosomal location, size, and
relative level of a genetic alteration. Further, we have analysed the
expression of the genes contained in the amplicons, in order to
identify those with a potential role in SCLC. Notch2 and CAP1 were
underexpressed, while HEYL, HPCAL4, and BMP8 were over-
expressed in SCLC in comparison to normal cell lines. IPT, BMP8,
and RLF were overexpressed in SCLC cells in which they were
genomically amplified in comparison to SCLC cells without
amplification. These data are in agreement with previous studies
that broadly implicate the BMP family in cancer, and specifically
implicate RLF in SCLC. Furthermore, we have observed increased
expression of HEYL, HPCAL4, and IPT, for which additional
investigation will be necessary to define their roles in cancer.
Genomic amplification is significant to cancer in that it can
directly result in increased expression of amplified genes (Hyman
et al, 2002). High-level amplifications have usually been seen
associated with a particular oncogene such as EGFR, MYC,o rERBB2
(Schwab, 1999). Here, we have described an amplicon containing the
MYCL1 oncogene, where additional genes are affected by the
genomic amplification. This demonstrates the importance of
integrating comprehensive genomic and gene expression analyses
where all genes in a region can be studied. Further, we have
demonstrated the benefit of a comparison among samples of the
same tumour type as well as against normal tissues in order to reveal
expression changes that may be functionally important.
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